Literature DB >> 21357924

Pulmonary arterial hypertension: a comparison between children and adults.

R J Barst1, S I Ertel, M Beghetti, D D Ivy.   

Abstract

The characteristics of pulmonary arterial hypertension (PAH), including pathology, symptoms, diagnosis and treatment are reviewed in children and adults. The histopathology seen in adults is also observed in children, although children have more medial hypertrophy at presentation. Both populations have vascular and endothelial dysfunction. Several unique disease states are present in children, as lung growth abnormalities contribute to pulmonary hypertension. Although both children and adults present at diagnosis with elevations in pulmonary vascular resistance and pulmonary artery pressure, children have less heart failure. Dyspnoea on exertion is the most frequent symptom in children and adults with PAH, but heart failure with oedema occurs more frequently in adults. However, in idiopathic PAH, syncope is more common in children. Haemodynamic assessment remains the gold standard for diagnosis, but the definition of vasoreactivity in adults may not apply to young children. Targeted PAH therapies approved for adults are associated with clinically meaningful effects in paediatric observational studies; children now survive as long as adults with current treatment guidelines. In conclusion, there are more similarities than differences in the characteristics of PAH in children and adults, resulting in guidelines recommending similar diagnostic and therapeutic algorithms in children (based on expert opinion) and adults (evidence-based).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357924      PMCID: PMC3128436          DOI: 10.1183/09031936.00056110

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  167 in total

1.  Pulmonary arterial hypertension and thyroid disease.

Authors:  A Ferris; T Jacobs; A Widlitz; R J Barst; J H Morse
Journal:  Chest       Date:  2001-06       Impact factor: 9.410

Review 2.  Pulmonary hypertension in the young.

Authors:  Sheila G Haworth
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

3.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

Authors:  Steeve Provencher; Olivier Sitbon; Marc Humbert; Ségolène Cabrol; Xavier Jaïs; Gérald Simonneau
Journal:  Eur Heart J       Date:  2006-01-23       Impact factor: 29.983

Review 4.  Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease.

Authors:  Bernard Thébaud; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2007-02-01       Impact factor: 21.405

5.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.

Authors:  Anna Fijalkowska; Marcin Kurzyna; Adam Torbicki; Grzegorz Szewczyk; Michal Florczyk; Piotr Pruszczyk; Monika Szturmowicz
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

6.  Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.

Authors:  O Sitbon; M Beghetti; J Petit; L Iserin; M Humbert; V Gressin; G Simonneau
Journal:  Eur J Clin Invest       Date:  2006-09       Impact factor: 4.686

7.  Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension.

Authors:  Jan T Kielstein; Stefanie M Bode-Böger; Gerrit Hesse; Jens Martens-Lobenhoffer; Attila Takacs; Danilo Fliser; Marius M Hoeper
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-04-28       Impact factor: 8.311

8.  Six-minute walk test in children and adolescents.

Authors:  Ralf Geiger; Alexander Strasak; Benedikt Treml; Klaus Gasser; Axel Kleinsasser; Victoria Fischer; Harald Geiger; Alexander Loeckinger; Joerg I Stein
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

9.  Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics.

Authors:  D S Celermajer; S Cullen; J E Deanfield
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

10.  Moderation of hypoxic vasoconstriction by infused arachidonic acid: role of PGI2.

Authors:  J G Gerber; N Voelkel; A S Nies; I F McMurtry; J T Reeves
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1980-07
View more
  57 in total

Review 1.  Pulmonary veno-occlusive disease: a misnomer?

Authors:  Cindy R Miller
Journal:  Pediatr Radiol       Date:  2012-02-05

Review 2.  Advances in pediatric pulmonary arterial hypertension.

Authors:  Dunbar Ivy
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

3.  Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.

Authors:  Margaux Boehler; Shirin Bruderer; Ivan Ulč; Jasper Dingemanse
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

4.  Sildenafil Use in Children with Pulmonary Hypertension.

Authors:  Jennifer L Cohen; Shannon N Nees; Gerson A Valencia; Erika B Rosenzweig; Usha S Krishnan
Journal:  J Pediatr       Date:  2018-11-02       Impact factor: 4.406

5.  Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension.

Authors:  Mei-Sing Ong; Mary P Mullen; Eric D Austin; Peter Szolovits; Marc D Natter; Alon Geva; Tianxi Cai; Sek Won Kong; Kenneth D Mandl
Journal:  Circ Res       Date:  2017-06-13       Impact factor: 17.367

Review 6.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

7.  Proximal pulmonary vascular stiffness as a prognostic factor in children with pulmonary arterial hypertension.

Authors:  Richard M Friesen; Michal Schäfer; D Dunbar Ivy; Steven H Abman; Kurt Stenmark; Lorna P Browne; Alex J Barker; Kendall S Hunter; Uyen Truong
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2019-02-01       Impact factor: 6.875

8.  Trends in pediatric pulmonary hypertension-related hospitalizations in the United States from 2000-2009.

Authors:  David B Frank; Matthew A Crystal; David L S Morales; Ken Gerald; Brian D Hanna; George B Mallory; Joseph W Rossano
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

9.  Inhaled Treprostinil Drug Delivery During Mechanical Ventilation and Spontaneous Breathing Using Two Different Nebulizers.

Authors:  Donna K Parker; Shuijie Shen; Jiang Zheng; D Dunbar Ivy; Dave N Crotwell; Justin C Hotz; Robert M DiBlasi
Journal:  Pediatr Crit Care Med       Date:  2017-06       Impact factor: 3.624

Review 10.  Pulmonary Hypertension in Children.

Authors:  Dunbar Ivy
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.